Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Kainate Receptors
More Information »Kainate receptors are members of the ionotropic class of glutamate receptors, which also includes NMDA and AMPA receptors. Kainate receptors have been identified both pre- and post-synaptically. They contribute to excitatory postsynaptic currents in many regions of the CNS.
Kainate Receptor Products
Agonists |
|
Cat.No. |
Product Name / Activity |
| 1107 | ATPA |
| Selective, potent GluR5 agonist | |
| 0269 | Domoic acid |
| Potent, selective kainate agonist | |
| 0307 | (S)-(-)-5-Iodowillardiine |
| Highly potent, subtype-selective kainate agonist | |
| 0222 | Kainic acid |
| Potent excitant and neurotoxin | |
| 2225 | MNI caged kainic acid |
| Caged kainic acid | |
| 0903 | SYM 2081 |
| Highly selective kainate agonist | |
Antagonists |
|
Cat.No. |
Product Name / Activity |
| 2728 | ACET |
| Potent antagonist of GluR5-containing kainate receptors | |
| 0190 | CNQX |
| Potent AMPA/kainate antagonist | |
| 1045 | CNQX disodium salt |
| Potent AMPA/kainate antagonist. More water soluble form of Cat. No. 0190 | |
| 0189 | DNQX |
| Selective non-NMDA antagonist | |
| 2312 | DNQX disodium salt |
| Selective non-NMDA antagonist. Water-soluble salt of DNQX (Cat. No. 0189) | |
| 0845 | Evans Blue tetrasodium salt |
| AMPA/kainate antagonist | |
| 2555 | GYKI 53655 hydrochloride |
| Kainate receptor antagonist; blocks GluK3 receptors | |
| 2187 | NS 3763 |
| Selective non-competitive kainate antagonist; selective for GLUK5 | |
| 3620 | Topiramate |
| GluR5 antagonist; inhibits carbonic anhydrase (CA) II and IV | |
| 1765 | UBP 282 |
| AMPA/kainate antagonist; distinguishes between motoneuron and dorsal root kainate receptors | |
| 2078 | UBP 296 |
| Selective, potent kainate antagonist; selective for GluR5-containing receptors | |
| 1766 | UBP 301 |
| Kainate receptor antagonist | |
| 2079 | UBP 302 |
| Selective, potent kainate antagonist; active enantiomer of UBP 296 (Cat. No. 2078) | |
| 3621 | UBP 310 |
| GLUK5 antagonist | |
| 2345 | ZK 200775 |
| Competitive AMPA/kainate antagonist | |
Ligand Sets |
|
Cat.No. |
Product Name / Activity |
| 1824 | Kainate Receptor Tocriset™ |
| Selection of 5 kainate receptor ligands (Cat. Nos. 0222, 1107, 0903, 1045 and 1454) | |
Other |
|
Cat.No. |
Product Name / Activity |
| 1777 | Arctigenin |
| Binds to kainate receptors; neuroprotective. Also inhibits IκBα phosphorylation and MEK1 | |
| 2207 | PDZ1 Domain inhibitor peptide |
| Disrupts interaction between GluR6 and PSD-95 PDZ1 domain | |
Related Categories
Quick Order
Find multiple products by catalog number
Pain Research Guide
Reserve your free copy
Highlights over 280 products for Pain research. Reserve copy
Calcium Imbalance and Neuroprotective Targets
Written by E. Besancon et al
'Calcium Imbalance and Neuro-protective Targets in Cerebral Ischemia & Brain Injury' highlights the key targets involved in stroke, trauma and neurodegeneration.
Neurobiology of Parkinson's Disease
Written by A. Schapira
'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.
Therapeutic Strategies in Schizophrenia
Written by J. Lieberman
'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.